Schizophrenia is now considered to be a severe mental disorder caused by complex gene-environment interactions. Brain-derived neurotrophic factor (BDNF) is involved in the development, differentiation, and plasticity of neurons. The Val66Met polymorphism has been associated with impaired neurocognitive function in healthy adults and has been identified as a risk site for a range of neuropsychiatric disorders, including schizophrenia. In this paper, the relationship between BDNFVal66Met polymorphism and schizophrenia is reviewed.

Penggang Li, Feihu Liu. Research Progress of Brain-Derived Neurotrophic Factor Val66Met Gene Polymorphism in Schizophrenia. International Journal of Frontiers in Medicine (2023), Vol. 5, Issue 5: 1-6. https://doi.org/10.25236/IJFM.2023.050501.

[1] John McGrath, Sukanta Saha, David Chant, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. [J]. Epidemiologic Reviews, 2008, 30: 67-76. 

[2] Egan Michael-F, Weinberger Daniel-R, Lu Bai. Schizophrenia, III: brain-derived neurotropic factor and genetic risk. [J]. The American journal of psychiatry, 2003, (7): 1242. 

[3] Delisi L-E. The significance of age of onset for schizophrenia. [J]. Schizophrenia bulletin, 1992, (2): 209-15. 

[4] Numata Shusuke, Ueno Shu-Ichi, Iga Jun-Ichi, et al. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism in schizophrenia is associated with age at onset and symptoms. [J]. Neuroscience letters, 2006, (1): 1-5. 

[5] Naoe Yui, Shinkai Takahiro, Hori Hiroko, et al. No association between the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and schizophrenia in Asian populations: Evidence from a case-control study and meta-analysis. [Z], 2007: 108-12. 

[6] Gourion David, Goldberger Celine, Leroy Sophie, et al. Age at onset of schizophrenia: interaction between brain-derived neurotrophic factor and dopamine D3 receptor gene variants. [Z], 2005: 1407-10. 

[7] Renata Suchanek, Aleksander Owczarek, Monika Paul-Samojedny, et al. BDNF val66met polymorphism is associated with age at onset and intensity of symptoms of paranoid schizophrenia in a Polish population. [J]. The Journal of Neuropsychiatry and Clinical Neurosciences, 2013, 25(1): 88-94. 

[8] Hang Xu, Jiesi Wang, Yongjie Zhou, et al. BDNF affects the mediating effect of negative symptoms on the relationship between age of onset and cognition in patients with chronic schizophrenia. [J]. Psychoneuroendocrinology, 2020, 125: 105121. 

[9] Meng-Meng Sun, Li-Min Yang, Yan Wang, et al. BDNF Val66Met polymorphism and anxiety/depression symptoms in schizophrenia in a Chinese Han population. [J]. Psychiatric Genetics, 2013, 23(3): 124-9. 

[10] Sun Mengmeng, Liu Lanfen, Yang Limin, et al. Association of brain-derived neurotrophic factor Val66Met gene polymorphism with clinical characteristics of first episode schizophrenia [J]. 2012. 

[11] Huang Tiao-Lai, Lee Chien-Te. Associations between brain-derived neurotrophic factor G196A gene polymorphism and clinical phenotypes in schizophrenia patients. [J]. Chang Gung medical journal, 2007, (5): 408-13. 

[12] Özlem Bolat Kaya, Hasan Kaya, Aybeniz Civan Kahve, et al. Association of BDNF Gene Val66Met Polymorphism with Suicide Attempts, Focused Attention and Response Inhibition in Patients with Schizophrenia. [J]. Noro Psikiyatri Arsivi, 2022, (2): 91-97. 

[13] Haisen Xia, Guangya Zhang, Xiangdong Du, et al. Suicide attempt, clinical correlates, and BDNF Val66Met polymorphism in chronic patients with schizophrenia. [J]. Neuropsychology, 2017, 32(2): 199-205. 

[14] Xiao-Jiao Bi, Xiao-Min Lv, Xian-Ying Ai, et al. Childhood trauma interacted with BDNF Val66Met influence schizophrenic symptoms. [J]. Medicine, 2018, 97(13): e0160. 

[15] Eric Huang, Nuwan C. Hettige, Gwyneth Zai, et al. BDNF Val66Met polymorphism and clinical response to [J]. The Pharmacogenomics Journal, 2018, 19: 269-276. 

[16] Hong Chen-Jee, Yu Younger-W-Y, Lin Ching-Hua, et al. An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. [J]. Neuroscience letters, 2003, (3): 206-8. 

[17] Gwyneth C M Zai, Clement C H Zai, Nabilah I Chowdhury, et al. The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. [J]. Progress in Neuro-psychopharmacology & Biological Psychiatry, 2012, 39(1): 96-101. 

[18] Anttila S, Illi A, Kampman O, et al. Lack of association between two polymorphisms of brain-derived neurotrophic factor and response to typical neuroleptics. [Z]. 2004: 885-90. 

[19] Xu Mingqing, Clair David-St, Ott Jurg, et al. Brain-derived neurotrophic factor gene C-270T and Val66Met functional polymorphisms and risk of schizophrenia: a moderate-scale population-based study and meta-analysis. [J]. Schizophrenia research, 2007, (1): 6-13. 

[20] Matea Nikolac Perkovic, Gordana Nedic Erjavec, Maja Zivkovic, et al. Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients. [J]. Psychopharmacology, 2014, 231(18): 3757-64. 

[21] Jiahong Liu, Pingping Wang, Leilei Sun, et al. The association between BDNF levels and risperidone-induced weight gain is dependent on the BDNF Val66Met polymorphism in antipsychotic-naive first episode schizophrenia patients: a 12-week prospective study. [J]. Translational Psychiatry, 2021, 11(1): 458. 

[22] Weinberger D-R, Gallhofer B. Cognitive function in schizophrenia. [J]. International clinical psychopharmacology, 1997: S29-36. 

[23] Zhang Chengcheng, Gu Xiaochu, Wang Qiang, et al. Association of cognitive function and clinical features with Val66Met polymorphism of brain-derived growth factor gene in patients with first-episode schizophrenia [J]. 2017. 

[24] Egan Michael-F, Kojima Masami, Callicott Joseph-H, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. [J]. Cell, 2003, (2): 257-69. 

[25] Dempster Emma, Toulopoulou Timothea, Mcdonald Colm, et al. Association between BDNF val66 met genotype and episodic memory. [J]. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 2005, (1): 73-5. 

[26] Ho Bengchoon, Milev Peter, O'leary Daniel-S, et al. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. [Z]. 2006: 731-40. 

[27] Xiangyang Zhang, Dachun Chen, Meihong Xiu, et al. Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. [J]. Human Genetics, 2012, 131(7): 1187-95. 

[28] Xuejuan Yang, Peng Liu, Jinbo Sun, et al. Impact of brain-derived neurotrophic factor Val66Met polymorphism on cortical thickness and voxel-based morphometry in healthy Chinese young adults. [J]. Plos One, 2012, 7(6): e37777. 

[29] Anthony O Ahmed, Samantha Kramer, Naama Hofman, et al. A Meta-Analysis of Brain-Derived Neurotrophic Factor Effects on Brain Volume in Schizophrenia: Genotype and Serum Levels. [J]. Neuropsychobiology, 2021, 80(5): 411-424. 

[30] Guo Fang, Li Wenqiang, Deng Yuefeng, et al. Study on the relationship between brain-derived neurotrophic factor gene VaL66Met polymorphism and brain structure in children with schizophrenia [J], 2012. 

[31] Paula Suárez-Pinilla, Roberto Roiz-Santiáñez, Victor Ortiz-García de la Foz, et al. BDNF Val66Met variants and brain volume changes in non-affective [J]. Progress in Neuro-psychopharmacology and Biological Psychiatry, 2013, 45: 201-206. 

[32] Yukako Kawasaki, Kenichi Oishi, Antonette Hernandez, et al. Brain-derived neurotrophic factor Val66Met variant on brain volumes in infants[J]. Brain Structure and Function, 2021, 226: 919-925.